文献速递临床试验与 GCP

液体水化预防平均至高危患者ERCP术后胰腺炎(FLUYT试验):随机对照试验研究方案

Fluid hydration to prevent post-ERCP pancreatitis in average- to high-risk patients receiving prophylactic rectal NSAIDs (FLUYT trial): study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2018-04-02

FLUYT试验为多中心、平行组、开放标签、优效性随机对照试验,计划纳入826例接受预防性直肠NSAIDs的中至高危ERCP患者,随机分为对照组(不补液或生理盐水,最大1.5 mL/kg/h且24小时不超过3L)或干预组(ERCP开始时60分钟内给予乳酸林格氏液20 mL/kg,随后8小时以3 mL/kg/h输注)。主要终点为ERCP术后胰腺炎发生率,次要终点包括PEP严重程度、水化相关并发症和成本效果。

要点

  • 在接受预防性直肠NSAIDs的中至高危ERCP患者中,评估围手术期水化联合直肠NSAIDs是否优于单用直肠NSAIDs。
  • 干预组使用乳酸林格氏液:ERCP开始时60分钟内20 mL/kg,随后8小时3 mL/kg/h。
  • 主要终点为ERCP术后胰腺炎发生率,次要终点包括严重程度、水化相关并发症和成本效果。

核心结论

  • 假设直肠NSAIDs联合围手术期水化可显著降低中至高危ERCP患者的ERCP术后胰腺炎发生率, compared to 单用直肠NSAIDs。

研究设计与样本

  • 多中心、平行组、开放标签、优效性随机对照试验,计划纳入826例接受预防性直肠NSAIDs的中至高危ERCP患者。

关键数值与推荐

  • 对照组:不补液或生理盐水,最大1.5 mL/kg/h且24小时不超过3L;干预组:乳酸林格氏液20 mL/kg于ERCP开始时60分钟内输注,随后8小时3 mL/kg/h。
  • 主要终点为ERCP术后胰腺炎发生率;次要终点包括PEP严重程度、水化相关并发症和成本效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) is the most common complication of ERCP and may run a severe course. Evidence suggests that vigorous periprocedural hydration can prevent PEP, but studies to date have significant methodological drawbacks. Importantly, evidence for its added value in patients already receiving prophylactic rectal non-steroidal anti-inflammatory drugs (NSAIDs) is lacking and the cost-effectiveness of the approach has not been investigated. We hypothesize that combination therapy of rectal NSAIDs and periprocedural hydration would significantly lower the incidence of post-ERCP pancreatitis compared to rectal NSAIDs alone in moderate- to high-risk patients undergoing ERCP. METHODS: The FLUYT trial is a multicenter, parallel group, open label, superiority randomized controlled trial. A total of 826 moderate- to high-risk patients undergoing ERCP that receive prophylactic rectal NSAIDs will be randomized to a control group (no fluids or normal saline with a maximum of 1.5 mL/kg/h and 3 L/24 h) or intervention group (lactated Ringer's solution with 20 mL/kg over 60 min at start of ERCP, followed by 3 mL/kg/h for 8 h thereafter). The primary endpoint is the incidence of post-ERCP pancreatitis. Secondary endpoints include PEP severity, hydration-related complications, and cost-effectiveness. DISCUSSION: The FLUYT trial design, including hydration schedule, fluid type, and sample size, maximize its power of identifying a potential difference in post-ERCP pancreatitis incidence in patients receiving prophylactic rectal NSAIDs. TRIAL REGISTRATION: EudraCT: 2015-000829-37 . Registered on 18 February 2015. ISRCTN: 13659155 . Registered on 18 May 2015.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Smeets XJNM, da Costa DW, Fockens P, et al. Fluid hydration to prevent post-ERCP pancreatitis in average- to high-risk patients receiving prophylactic rectal NSAIDs (FLUYT trial): study protocol for a randomized controlled trial. Trials. 2018. PMID: 29606135. doi:10.1186/s13063-018-2583-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。